Full Press Release Details
| NEWS RELEASE | |
| CONTACT : | |
| CONMED Corporation | |
| Todd W. Garner | |
| Chief Financial Officer | |
| ToddGarner@conmed.com |
CONMED Corporation Announces Strategic Exit
from Gastroenterology Product Lines
Concludes Distribution
Agreement with Gore for VIABIL in the United States and Canada, Effective January 1, 2026
Announces Intent to Exit
Remaining Products in its Gastroenterology Product Portfolio
Reaffirms 2025 Revenue and EPS Guidance
Largo, Fla. - December 5, 2025 - CONMED Corporation
(NYSE: CNMD) today announced its intention to exit its gastroenterology product lines as part of its broader portfolio optimization
strategy. This exit allows CONMED to fully align operations and resources within its core markets-minimally invasive, robotic, and
laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair.
"Today's announcement reflects a positive step in our strategic
portfolio review and our commitment to focus on areas where CONMED can lead in innovation and deliver the greatest impact- minimally
invasive surgery, smoke evacuation, and orthopedic soft tissue repair," said Patrick J. Beyer, CONMED's President and Chief
Executive Officer. "By concentrating our resources on our core growth platforms, we are positioning CONMED for long-term success
and continued leadership in surgical innovation. We are proud of the contributions our gastroenterology team has made to advancing patient
care and supporting clinicians over the years, and we thank them for their dedication and impact on the business."
Distribution Agreement with Gore
Under the terms of its distribution agreement with W. L. Gore &
Associates, Inc. ("Gore"), CONMED has held exclusive U.S. and Canadian distribution rights for the Gore VIABIL biliary
stent. As previously disclosed in its latest 10-Q filing, CONMED did not plan to renew this agreement beyond December 31, 2026. Following
a strategic review, the Company elected to accelerate this timeline, concluding the agreement effective January 1, 2026. Financial terms
of the agreement were not disclosed.
Financial Considerations Related to the Exit
CONMED Confidential - Do Not Distribute, Transmit, or Replicate without
About CONMED Corporation
CONMED is a medical technology company that provides
devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in
a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information,
visit www.conmed.com.
Forward-Looking Statements
This press release may contain forward-looking statements based on
certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to
differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to
general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking
statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year
ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q and
other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking
statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's
performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but
there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements
will actually occur or prove to be correct.
CONMED Confidential - Do Not Distribute, Transmit, or Replicate without